Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol
(CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome
(SWS) and drug resistant epilepsy.